Short Interest in Medicus Pharma Ltd (NASDAQ:MDCX) Increases By 171.5%

Medicus Pharma Ltd (NASDAQ:MDCX) saw a significant increase in short interest in July. As of July 15th, there was short interest totaling 2,838,930 shares, an increase of 171.5% from the June 30th total of 1,045,598 shares. Approximately 5.5% of the company’s shares are short sold. Based on an average trading volume of 1,143,133 shares, the short-interest ratio is currently 2.5 days.

Analyst Upgrades and Downgrades

MDCX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. Finally, Roth Capital started coverage on shares of Medicus Pharma in a research note on Tuesday, April 21st. They issued a “buy” rating for the company. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

Institutional Trading of Medicus Pharma

Several institutional investors and hedge funds have recently modified their holdings of MDCX. Jane Street Group LLC bought a new position in Medicus Pharma in the second quarter worth approximately $41,000. HRT Financial LP purchased a new position in Medicus Pharma during the 4th quarter worth $42,000. Osaic Holdings Inc. raised its position in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares in the last quarter. Commonwealth Equity Services LLC raised its position in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares in the last quarter. Finally, May Hill Capital LLC lifted its holdings in shares of Medicus Pharma by 100.0% in the 4th quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock worth $55,000 after buying an additional 17,811 shares during the period.

Medicus Pharma Price Performance

Shares of NASDAQ:MDCX traded down $0.05 on Monday, hitting $0.32. 3,253,793 shares of the company’s stock were exchanged, compared to its average volume of 3,624,572. The stock has a market capitalization of $18.03 million, a price-to-earnings ratio of -0.12 and a beta of -0.05. Medicus Pharma has a 12 month low of $0.25 and a 12 month high of $3.05. The business’s 50 day simple moving average is $0.37 and its two-hundred day simple moving average is $0.65.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). Equities analysts forecast that Medicus Pharma will post -0.51 EPS for the current fiscal year.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.